Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.
BioLineRx Ltd. develops oncology and rare-disease therapies, with recurring updates centered on GLIX1, APHEXDA (motixafortide), and motixafortide development in solid tumors.
Company news covers GLIX1 clinical development for glioblastoma and other solid tumors under its Hemispherian collaboration, intellectual-property developments tied to GLIX1, financial results, and corporate updates. APHEXDA is approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma and is commercialized by partners, while BioLineRx has retained motixafortide rights for solid-tumor programs including metastatic pancreatic cancer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a biopharmaceutical company in oncology, has announced that it has regained compliance with the Nasdaq minimum bid price requirement. This follows a notification on November 2, 2022, when the company failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. Nasdaq granted a 180-day period for compliance, which the company successfully achieved by maintaining a closing bid price above $1.00 from April 10 to April 21, 2023. As a result, BioLineRx's American Depository Shares will remain listed on Nasdaq. The company is also advancing its lead product, motixafortide, with a New Drug Application accepted by FDA and a PDUFA date set for September 9, 2023.